July 31 (Reuters) – AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
A history of Warner Bros — from old Hollywood to streaming era
Sept 21 (Reuters) - Paramount Skydance on Monday reached a settlement with California and 11…
Texas Governor Abbott halts all state-issued permits for data centers until grid audit is complete
By Liz Hampton and Laila Kearney DENVER/NEW YORK, Sept 21 (Reuters) - Texas Governor Greg…
Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
By Noel Randewich and Johann M Cherian Sept 21 (Reuters) - The Nasdaq surged to…
